Ironwood Pharmaceuticals (IRWD) 2024 Wells Fargo Healthcare Conference summary

Company overview and strategic focus

• Focused on gastrointestinal (GI) medicines, with Linzess as the lead asset showing durable growth and exceeding $1 billion in sales.

• Strategic priorities include maximizing Linzess profitability through 2029, expanding the pipeline, and generating strong cash flow.

• Acquired VectivBio for apraglutide, a best-in-class GLP-2 for short bowel syndrome, with positive phase III data and regulatory submission planned for early next year.

• Licensed CNP-104 for primary biliary cholangitis, aiming to be a disease-modifying agent with data expected soon.

Linzess performance and market dynamics

• Linzess demand remains strong, with nearly 50% market share and steady growth, but faces pricing and Medicaid mix headwinds.

• Medicaid volume increased, impacting net sales due to rebate changes and removal of the AMP cap, leading to a top-line shock in 2024.

• Commercial business remains stable, and the impact of the Medicaid mix shift is expected to be absorbed going forward.

• Long-term growth is expected to return to low single digits after absorbing current shocks, with payer access being a key focus.

Financial outlook and operational strategy

• Despite pricing pressures, Linzess is expected to continue generating significant cash flow through 2029.

• Apraglutide launch is targeted for 2026, with limited increase in G&A and expenses anticipated.

• R&D spend peaked this year due to multiple advanced trials; focus will shift to commercial launch preparation in 2025.

• Options to optimize spend and increase free cash flow are being evaluated.